Euroopa Liit - islandi - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamíð - flogaveiki, partial - antiepileptics, - lacosamide ucb er ætlað eitt og sér og venjulega meðferð í meðferð á hluta-upphaf flog með eða án efri almenn ákvörðun er tekin í fullorðnir, unglingum og börn, frá 4 ára aldri með flogaveiki.

Euroopa Liit - islandi - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, álag cvd 103-hgr, lifandi - cholera - bóluefni - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. Þetta bóluefni ætti að vera notuð í samræmi við opinbera tillögur.

Euroopa Liit - islandi - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - beinþynning - lyf til að meðhöndla beinsjúkdóma - evenity er ætlað í meðferð alvarlega beinbrot í tíðahvörf konur í mikilli hættu af beinbrot.

Euroopa Liit - islandi - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Euroopa Liit - islandi - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - Ónæmisbælandi lyf - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

galderma nordic ab - trifarotenum - krem - 50 míkróg/g

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

glenmark pharmaceuticals nordic ab* - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/500 míkróg/skammt

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

glenmark pharmaceuticals nordic ab* - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/100 míkróg/skammt

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

navamedic asa - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

vital pharma nordic aps - dexamethasonum natríumfosfat - stungulyf/innrennslislyf, lausn - 4 mg/ml